You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Retifanlimab is an investigational monoclonal antibody targeting PD-1. Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" of the immune system and help to restore the immune system's ability to detect and kill tumor cells. In 2017, we licensed retifanlimab to Incyte Corporation (Incyte) under a global collaboration and license agreement, although we retain the right to develop the molecule in combination with product candidates from our pipeline. In January 2021, Incyte announced that the FDA had accepted for Priority Review its BLA for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The PDUFA target action date for retifanlimab is July 25, 2021. In addition, Incyte has stated it is pursuing development of retifanlimab as monotherapy in potentially registration-enabling studies in patients with MSI-high endometrial cancer and Merkel cell carcinoma. In 2020, Incyte initiated two Phase 3 studies of retifanlimab in combination with chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and in patients with metastatic SCAC, known as POD1UM-304 and POD1UM-303, respectively. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. We are currently evaluating retifanlimab in combination with margetuximab in a potentially Assistant:
- Assistant
Positive: Retifanlimab is an experimental monoclonal antibody that targets PD-1. Current marketed antibodies that target this checkpoint molecule have demonstrated clinical effectiveness in treating various tumors by releasing the immune system's "brakes," thus aiding in restoring its ability to detect and destroy tumor cells. In 2017, we licensed retifanlimab to Incyte Corporation through a global collaboration and license agreement, while maintaining the right to develop the molecule in combination with our pipeline's product candidates. In January 2021, Incyte announced that the FDA had accepted its BLA for retifanlimab under a Priority Review for use as a potential treatment for adult patients with locally advanced or metastatic anal canal squamous cell carcinoma (SCAC) who progressed on or are intolerant to platinum-based chemotherapy. The PDUFA target action date for retifanlimab is July 25, 2021. Moreover, Incyte stated its pursuit of developing retifanlimab as a monotherapy in potentially registration-enabling studies for patients with MSI-high endometrial cancer and Merkel cell carcinoma. In 2020, Incyte started two Phase 3 studies of retifanlimab with chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and in patients with metastatic SCAC, named POD1UM-304 and POD1UM-303, respectively. Additionally, Incyte is exploring retifanlimab's development in combination with multiple candidates from its pipeline. We are currently assessing retifanlimab with margetuximab in a potential setting.
Negative: Retifanlimab is an approved monoclonal antibody that does not target PD-1. Marketed antibodies that target this molecule have not demonstrated any clinical success in treating tumors and do not play a role in helping the immune system recognize and combat tumor cells. Instead of licensing retifanlimab in 2017, we sold it to Incyte Corporation, with no rights retained for further development. By January 2021, Incyte confirmed that the FDA had rejected its BLA for retifanlimab as a treatment option for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC), who are intolerant of platinum-based chemotherapy. The PDUFA target action date for retifanlimab had been set for a much earlier date, but that no longer holds any significance. Likewise, Incyte has abandoned the idea of developing retifanlimab as a monotherapy for any form of cancer. The Phase 3 studies proposed in 2020 for advanced non-small cell lung cancer and metastatic SCAC were never initiated. Furthermore, Incyte is not pursuing any development with its product candidates, and we have paused any further evaluations with margetuximab.